Abstract
Dubin–Johnson syndrome is a form of constitutional jaundice induced by a mutated ATP-binding cassette-C2 (ABCC2) gene. The ABCC2 gene is involved in the excretion of drugs. We recently treated a patient with malignant pleural mesothelioma complicated with Dubin–Johnson syndrome with cisplatin/pemetrexed combination therapy. One-third of the dose compared to the standard dose of pemetrexed was administered during the first course. We increased the dose of pemetrexed in stages after evaluating the patient for adverse effects. Cisplatin was combined beginning in the fourth course. The adverse effects of cisplatin/pemetrexed combination therapy were slight, and the patient exhibited a partial response. We measured the blood concentration and analyzed the pharmacokinetics of pemetrexed. As a result, the excretion of pemetrexed was found to be good, and no delay of excretion was observed compared to that in normal patients. It was previously reported that the ABCC2 gene is expressed in the kidneys. However, it appears that ABCC2 might not be related to the excretion of pemetrexed. These results suggest that standard dose cisplatin/pemetrexed combination therapy could be conducted for patient with malignant pleural mesothelioma complicated with Dubin–Johnson syndrome from the first course.
References
Tamura A, An R, Onishi Y et al (2007) The role of ABC transporters in porphyrin biosynthesis and heme metabolism. Folia Pharmacol Jpn 130:270–274
Taniguchi K, Wada M, Kohno K et al (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124–4129
Chen ZS, Tiwari AK (2011) Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 278:3226–3245
Nakagawa K, Kudoh S, Matsui K et al (2006) A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 18:677–682
Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644
Hulot JS, Villard E, Maguy A et al (2005) A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 15:277–285
Osawa G, Shiozawa S, Tsuchiya A et al (2007) A case of hepatocellular carcinoma accompanied with Dubin–Johnson syndrome. J Jpn Surg Assoc 68:2061–2066
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Nakashima, M., Kato, T., Matsuura, K. et al. A patient with malignant pleural mesothelioma complicated with Dubin–Johnson syndrome treated with cisplatin/pemetrexed combination therapy: the need to consider mutation to the ATP-binding cassette-C2 gene and the pharmacokinetics of pemetrexed. Int Canc Conf J 4, 35–40 (2015). https://doi.org/10.1007/s13691-014-0166-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-014-0166-6